HIF Inhibitor Formulation Photostability via Light Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid lack photostability, leading to decomposition upon light exposure, which has not been effectively addressed in existing formulations.
Innovation Solution
A pharmaceutical formulation comprising [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid combined with a pharmaceutically acceptable excipient and an effective amount of a photostabilizing agent, such as titanium dioxide and specific dyes, to prevent photodegradation, with the photostabilizing agent blocking light in the 200-550 nm wavelength range.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Compound A is formulated without photostabilizing agents, then the formulation is simpler and manufacturing is easier, but the compound decomposes upon light exposure
Solution Approach 1:
The patent introduces photostabilizing agents (titanium dioxide and dyes) as intermediary substances that mediate between the active compound and light. These agents absorb or block harmful light wavelengths before they can reach and decompose Compound A, thereby protecting the active ingredient while maintaining formulation feasibility
Solution Approach 2:
The patent creates a composite pharmaceutical formulation by combining Compound A with photostabilizing agents (titanium dioxide and dyes). This composite structure integrates the therapeutic function of Compound A with the protective function of the photostabilizing agents, achieving both stability and manufacturability
2Reliability
If photostabilizing agents are added to protect Compound A from light, then photostability is improved, but the formulation becomes more complex
Solution Approach 1:
The patent applies photostabilizing agents specifically where needed - in the coating layer and capsule shell - rather than uniformly throughout the entire formulation. This localized application provides photoprotection exactly where the compound is most vulnerable to light exposure while minimizing unnecessary additives in the core formulation
Solution Approach 2:
The patent utilizes dyes with specific color properties (yellow, orange, red) that absorb light in the 200-550 nm wavelength range. The color characteristics of these dyes are directly related to their light-absorbing capability, allowing selection of dyes based on their spectral properties to achieve photostability
3Reliability
If the photostabilizing agent blocks light in the 200-550 nm range, then photodegradation is reduced to less than 0.2% w/w, but the formulation requires specific wavelength blocking capabilities
Solution Approach 1:
The patent specifies precise parameter ranges for the photostabilizing agents, including dyes that block light in the 200-550 nm wavelength range and titanium dioxide as a complementary agent. By controlling these spectral parameters, the formulation achieves photodegradation resistance of less than 0.2% w/w under ICH lighting conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly reduces photodegradation, limiting the amount of photodegradation product to less than 0.2% w/w, thereby maintaining the stability and efficacy of the active ingredient under light exposure conditions.
Implementation Method 1
the photostabilizing agent blocks light at a wavelength range of between about 200 and about 550 nm
Implementation Method 2
the photostabilizing agent comprises titanium dioxide and at least one additional dye
Data Source
AI summary
The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.